semaglutide and tirzepatide. Semaglutide/Tirzepatide: Beyond Weight Loss: Shamsah Amersi, MD: OB-GYNs Fridays | GLP-1 Telehealth |

Clinical data from tirzepatide trials demonstrates that patients reaching maintenance doses of 10 to 15 milligrams experience average weight loss of 20 to 22% of baseline body weight over six months

This condition, known as non-alcoholic fatty liver disease (NAFLD), is becoming increasingly common, particularly among individuals who are overweight or obese

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Mechanism of Action Pancreas: Increases glucose-dependent insulin secretion, decreases glucagon Brain: Enhances satiety Stomach: Slows gastric emptying Main Indications Type 2 diabetes mellitus Obesity/weight management Cardiovascular risk reduction Common Drugs Exenatide Liraglutide Semaglutide Dulaglutide Tirzepatide (dual GIP/GLP-1 agonist) Key Benefits Significant weight loss Low hypoglycemia risk Cardiovascular protection Major Side Effects Nausea/vomiting (most common) Pancreatitis (rare) Thyroid C-cell tumors (boxed warning) Contraindications Multiple Endocrine Neoplasia type 2 (MEN2) Personal/family history of medullary thyroid carcinoma #Pharmaceuticals #GLP1 #Diabetes #Obesity #Healthcare #Biotech #ClinicalResearch #Endocrinology #MedicalAffairs GLP-1 Analogues: Mechanism, Indications, and Side Effects GLP-1 Analogues : Definition Synthetic versions of the natural hormone GLP-1 (glucagon-like peptide-1) that are resistant to DPP-4 breakdown, providing longer-lasting effects